<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03178864</url>
  </required_header>
  <id_info>
    <org_study_id>H17-00440</org_study_id>
    <nct_id>NCT03178864</nct_id>
  </id_info>
  <brief_title>Study of Rivaroxaban for CeREbral Venous Thrombosis</brief_title>
  <acronym>SECRET</acronym>
  <official_title>Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Early Anticoagulation With Rivaroxaban Versus Standard of Care in Determining Safety at 365 Days in Symptomatic Cerebral Venous Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      SECRET examines the safety of rivaroxaban versus standard-of-care for treatment of&#xD;
      symptomatic cerebral venous thrombosis, initiated within 14 days of diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SECRET is an open-label, randomized, controlled, phase II study that will assess the safety&#xD;
      of rivaroxaban, a non-vitamin K antagonist oral anticoagulant (NOAC), compared with&#xD;
      standard-of-care (unfractionated or low-molecular weight heparin with transition to warfarin&#xD;
      [INR 2.0-3.0], or continued low molecular-weight heparin) for cerebral venous thrombosis.&#xD;
      Recruitment will occur at 17 high-volume stroke research centres across Canada over 3 years.&#xD;
      During the pilot phase, 50 adult patients within 14 days of symptomatic cerebral venous&#xD;
      thrombosis diagnosis will be randomized to receive rivaroxaban 20 mg daily versus standard of&#xD;
      care (warfarin or low-molecular weight heparin). Patients will be followed for 1 year. The&#xD;
      feasibility of recruitment will be tested during the pilot phase and outcomes refined for a&#xD;
      future Phase III trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite rate of all-cause mortality, symptomatic intracranial bleeding, major extracranial bleeding</measure>
    <time_frame>180 days</time_frame>
    <description>Symptomatic intracranial bleeding is defined as a new symptomatic intracranial hemorrhage OR worsening existing intracranial hemorrhage with a &gt;33% change in hematoma volume, AND either an NIHSS score increase of 4 or more points, or a change in level of consciousness as per NIHSS item 1a, AND the clinical change is thought to be attributable to the hemorrhage.&#xD;
Major extracranial bleeding is defined as bleeding in a critical area or organ, including intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a drop in hemoglobin by 20 g/L or more, leading to transfusion of 2 or more units of whole blood or red cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>180 days</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial bleeding</measure>
    <time_frame>180 days</time_frame>
    <description>Symptomatic intracranial bleeding is defined as a new symptomatic intracranial hemorrhage OR worsening existing intracranial hemorrhage with a &gt;33% change in hematoma volume, AND either an NIHSS score increase of 4 or more points, or a change in level of consciousness as per NIHSS item 1a, AND the clinical change is thought to be attributable to the hemorrhage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major extracranial bleeding</measure>
    <time_frame>180 days</time_frame>
    <description>Major extracranial bleeding is defined as bleeding in a critical area or organ, including intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a drop in hemoglobin by 20 g/L or more, leading to transfusion of 2 or more units of whole blood or red cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent venous thromboembolism</measure>
    <time_frame>180 days or end of anticoagulation, whichever is sooner</time_frame>
    <description>any thrombosis at a new site including cerebral venous thrombosis in a separate localization from index event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding or clinically relevant non-major bleeding</measure>
    <time_frame>180 days or end of anticoagulation, whichever is sooner</time_frame>
    <description>A clinically relevant minor bleed is an acute or subacute clinically overt bleed that does not meet the criteria for a major bleed but prompts a clinical response, in that it leads to at least one of: (a) a hospital admission for bleeding, or (b) a physician guided medical or surgical treatment for bleeding, or (c) a change in antithrombotic therapy (including interruption or discontinuation or study drug)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial or complete recanalization</measure>
    <time_frame>180 or 365 days</time_frame>
    <description>Partial or complete recanalization between baseline and last study venogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional independence</measure>
    <time_frame>365 days</time_frame>
    <description>modified Rankin Scale 0-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced functional dependence</measure>
    <time_frame>365 days</time_frame>
    <description>shift of one or more modified Rankin Scale categories to reduced functional dependence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care resource utilization</measure>
    <time_frame>365 days</time_frame>
    <description>Cost in Canadian dollars of number of hospitalizations (length of stay, critical care unit use), emergency room visits, unscheduled outpatient consultations, postacute care (including home care, rehabilitation stays or long-term care)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Health Questionnaire (PHQ)-9 score</measure>
    <time_frame>365 days</time_frame>
    <description>Change in PHQ-9 score between baseline and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQOL 5-Dimensions (EQ-5D) score</measure>
    <time_frame>365 days</time_frame>
    <description>Change in EQ-5D score between baseline and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Assessment score</measure>
    <time_frame>365 days</time_frame>
    <description>Change in fatigue assessment score between baseline and end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Impact Test - 6 score</measure>
    <time_frame>365 days</time_frame>
    <description>Change in Headache Impact Test - 6 score between baseline and Day 180 (score = 36-78, where a higher score indicates a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment score</measure>
    <time_frame>365 days</time_frame>
    <description>Change in performance on the Montreal Cognitive Assessment between baseline and end of study (score = 0-30, where a higher score indicates a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health toolbox - Cognitive battery score</measure>
    <time_frame>365 days</time_frame>
    <description>Change in performance on the cognitive battery of the National Institutes of Health toolbox between baseline and end of study (where a higher score indicates a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Boston cookie theft picture description task</measure>
    <time_frame>365 days</time_frame>
    <description>Change in spontaneous speech between baseline and end of study. Components of spontaneous speech include lexical features (part-of-speech, word types and frequencies), syntactic complexity, grammaticality, fluency, vocabulary richness, and acoustic features.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cerebral Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Unfractionated heparin Low-molecular weight heparin (dalteparin, enoxaparin, tinzaparin) Warfarin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Rivaroxaban 20 mg daily (15 mg daily in participants with a CrCl 30-49 mL/min as per the Cockroft-Gault equation)</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Accepted standard of care as per American Heart Association/American Stroke Association Guidelines (initial use of unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist or continuation with low-molecular weight heparin) with choice of agent at the treating physician's discretion.</description>
    <arm_group_label>Standard of care</arm_group_label>
    <other_name>Heparin, Coumadin, Fragmin, Lovenox, Innohep</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Patients aged 18 and above&#xD;
&#xD;
          2. New diagnosis of symptomatic cerebral venous thrombosis as confirmed on CT venogram or&#xD;
             MR venogram&#xD;
&#xD;
          3. Ability to randomize within 14 days of neuroimaging-confirmed diagnosis&#xD;
&#xD;
          4. The treating clinician is of the opinion that the patient is appropriate for oral&#xD;
             anticoagulation as per standard of care&#xD;
&#xD;
          5. Patient or legally authorized representative is able to give written informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Patient has known antiphospholipid antibody syndrome (APLS; lupus anticoagulant,&#xD;
             anti-beta 2-glycoprotein I antibodies, and anticardiolipin antibody) by Sapporo-Sydney&#xD;
             criteria with a previous history of venous or arterial thrombosis&#xD;
&#xD;
          2. Patient is anticipated to require invasive procedure (e.g. lumbar puncture,&#xD;
             thrombectomy, hemicraniectomy) prior to initiation of oral anticoagulation**&#xD;
&#xD;
          3. Patient is unable to swallow due to depressed level of consciousness†&#xD;
&#xD;
          4. Impaired renal function (i.e., CrCl &lt; 30 mL/min using Cockroft-Gault equation)&#xD;
&#xD;
          5. Pregnancy; if a woman is of childbearing potential a urine or serum beta human&#xD;
             chorionic gonadotropin (β-hCG) test is positive&#xD;
&#xD;
          6. Breastfeeding at the time of randomization&#xD;
&#xD;
          7. Bleeding diathesis or other contraindication to anticoagulation&#xD;
&#xD;
          8. Any concurrent medical condition requiring mandatory antiplatelet or anticoagulant use&#xD;
&#xD;
          9. Concomitant use of strong CYP3A4 inducers (e.g., ongoing use of dilantin,&#xD;
             carbamazepine, HIV protease inhibitors) or CYP3A4 inhibitors (e.g., diltiazem,&#xD;
             ketoconazole)&#xD;
&#xD;
         10. Patient has a severe or fatal comorbid illness that will prevent improvement, or&#xD;
             cannot complete follow-up due to the same, or cannot complete follow-up due to&#xD;
             co-morbid non-fatal illness, non-residence in the city, or for any other known reason&#xD;
             for which follow-up would be impossible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thalia S Field, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thalia S Field, MD FRCPC</last_name>
    <phone>604-875-4554</phone>
    <email>thalia.field@ubc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vanessa Dizonno, MSc</last_name>
    <phone>604-875-4111</phone>
    <phone_ext>67814</phone_ext>
    <email>vanessa.dizonno@ubc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Sage</last_name>
      <phone>(403) 483-1144</phone>
      <email>Kayla.Sage@albertahealthservices.ca</email>
    </contact>
    <contact_backup>
      <last_name>Supriya Save, MSc, PhD</last_name>
      <phone>403 944 2370</phone>
      <email>Supriya.save@ahs.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Hill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shelagh Coutts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paige Fairall</last_name>
      <phone>780-248-1521</phone>
      <email>fairall@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Brian Buck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kelowna General Hospital</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1T2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie McClelland, RN</last_name>
      <phone>250-980-1376</phone>
      <email>Marie.Mcclelland@interiorhealth.ca</email>
    </contact>
    <contact_backup>
      <last_name>Mackenzie Cheyne</last_name>
      <email>Mackenzie.Cheyne@interiorhealth.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Aleksander Tkach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elsadig Elamin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Columbian Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Princess King-Azote</last_name>
      <email>princess.king-azote@ubc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa Dizonno, MSc</last_name>
      <phone>6048754111</phone>
      <phone_ext>67814</phone_ext>
      <email>vanessa.dizonno@ubc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Laura Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheyanne Vandervelde</last_name>
      <email>vandervelc@hhsc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Cathy Moreau</last_name>
      <email>moreaucat@hhsc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Kanjana Perera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Nguyen, MSc</last_name>
      <email>aln4@queensu.ca</email>
    </contact>
    <investigator>
      <last_name>Ramana Appireddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeinab Daham</last_name>
      <phone>613-798-5555</phone>
      <phone_ext>16211</phone_ext>
      <email>zdaham@ohri.ca</email>
    </contact>
    <investigator>
      <last_name>Dylan Blacquiere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William To, MSc</last_name>
      <phone>1-416-346-4148</phone>
      <phone_ext>13-4980</phone_ext>
      <email>William.To@uhnresearch.ca</email>
    </contact>
    <investigator>
      <last_name>Aleksandra Pikula, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nandy-Shelwine Simon, MSc</last_name>
      <phone>5148908000</phone>
      <phone_ext>26242</phone_ext>
      <email>nandy-shelwine.simon.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Céline Odier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Gioia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shrijal Bhavsar</last_name>
      <phone>(306) 229-1669</phone>
      <email>shrijal.bhavsar@usask.ca</email>
    </contact>
    <contact_backup>
      <last_name>Lilian Urroz, MD</last_name>
      <phone>306-844-1487</phone>
      <email>lilian.urroz@usask.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Brett Graham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Thalia Field</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cerebral venous thrombosis</keyword>
  <keyword>anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Upon completion of the SECRET Trial, a public use database will be prepared by stripping any and all personal identifiers. The public use database, consisting of several data files, should contain: (1) baseline and demographic characteristics; (2) outcomes assessments; (3) CT/MRI data; (4) concomitant medications and procedures; and (5) adverse events. Each data file is made available as a formatted SAS dataset or other electronic format. The data files are distributed along with the data dictionary and a brief instruction (&quot;Readme&quot;) file. These data files will be made available to the public only after all major manuscripts (including secondary analysis papers) of the Trial are accepted for publication in peer-reviewed journals.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

